New drug combo tested to fight Leukemia's return after transplant

This early-stage study tested two immunotherapy drugs, nivolumab and ipilimumab, in patients with high-risk or returning acute myeloid leukemia or myelodysplastic syndrome who had already received a donor stem cell transplant. The main goals were to find safe doses and check for side effects, particularly a serious transplant complication called graft-versus-host disease. Researchers also wanted to see if these drugs could help the immune system better attack any remaining cancer cells.